The concentrations of aztreonam in human tissues obtained during surgery were measured after a single 2-g intravenous dose. The average concentration in the skeletal muscle, atrial appendage, lung, sternum, pericardial fluid, endometrium, myometrium, fallopian tube, and ovary varied from 3 to 33 ,ug/g (or ,ug/mI). These concentrations significantly exceed the MIC for 90% of strains for most members of the family Enterobacteriaceae.
Single parenteral doses of aztreonam produce significant concentrations in serum (14) , cerebrospinal fluid (3, 5) , bile (9) , blister fluid (17), peritoneal fluid (16) , peritoneal dialysate (4) , the prostate (8) , and bronchial secretions (1) . The study reported here was undertaken to determine the extent of aztreonam penetration into tissues and fluids obtained during thoracic and gynecologic surgery which had not been evaluated previously.
Patients. Fifty-one patients scheduled for elective thoracic surgery at the Buffalo Veterans Administration Medical Center and 18 patients scheduled for elective gynecologic surgery at the University of Iowa Hospital and Clinic were enrolled in this study. All buffer) per g of homogenate. The diluted homogenates were then centrifuged, and the supernatant was decanted and saved.
The pellet was extracted twice with 5 ml of 30% methanol (in pH 6 phosphate buffer) per g of pellet. Filtered (Millex, 0.45-[im pore size; Millipore Corp., Bedford, Mass.) extracts were assayed by high-pressure liquid chromatography equipment that was previously described (11) . Serum obtained simultaneously with thoracic tissues and fluids was assayed by a previously described high-pressure liquid chromatography method (11) , and a similar method was used to assay pericardial and pleural fluid.
Commercially obtained samples of tissue or body fluid (Agrilab Inc., Bridgewater, N.J.) were mixed with known amounts of aztreonam at the time the specimens were obtained from study patients. These spiked samples were assayed for aztreonam, and the results were used to correct clinical specimen assay results for losses during storage.
The limit of detection, assay coefficient of variability, and recovery from spiked samples for each type of high-pressure liquid chromatography assay ranged from 0.5 to 1.3 ,ig/g (or jLg/ml), 5.3 to 14.7%, and 80.4 to 101%, respectively.
Gynecologic tissue and simultaneous serum were assayed by microbiologic methods. The method for serum was previously described (14) .
Frozen tissue samples were thawed and cut into small pieces, and 0.2-g samples were weighed into a labeled test tube. These samples were refrozen at -78°C until assayed. On the day of assay, the samples were extracted by a procedure similar to that used for the high-pressure liquid chromatography assay of thoracic tissues. The extracts were added to cylinders on seeded agar plates (Penassay Seed Agar-B263; Difco Laboratories, Detroit, Mich.) and incubated at 37°C for 16 The hemoglobin content of tissue and fluid specimens was tained during thoracic surgery were generally similar to or used to correct the assay results for aztreonam in contamiexceeded mean drug concentrations produced in these tisnating blood (8) . Samples that contained more than 50% sues after similar doses of cefQtaxime, ceftazidime, or blood were excluded. cefonacid (7, 13, 10) . Mean aztreonam levels in gynecologic The aztreonam concentrations in tissues and fluids obtissues exceeded mean drug levels produced after a 7-g dose tained during thoracic and gynecologic surgery are shown in of cefmenoxime or a 1-g dose of moxalactam (2, 12) . Tables 1 and 2 . Mean concentrations in the skeletal muscle,
The mean tissue and fluid aztreonam concentrations obatrial appendage, lung, pericardial fluid, endometrium, served in this study were 3 to 33 times the MIC for 90% of myometrium, ovary, and fallopian tube ranged between 4 strains for most members of the family Enterobactericeae and 33 p.g/g (or ,ug/ml), depending on the type of specimen (15) . These results provide support for the reported theraand the time after administration of the drug. Mean sternum peutic efficacy of aztreonam in skin, soft tissue, pulmonary, concentrations ranged between 3 and 6 ,ug/g. Only three and gynecologic infections (6) 
